Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients

Leukemia

Volumn 22, Issue 4, 2008, Pages 870-873

  Butcher, C M ^a   Hahn, U ^b   To, L B ^c   Gecz, J ^d   Wilkins, E J ^e   Scott, H S ^e   Bardy, P G ^b   D'Andrea, R J ^a,b,d  

^a CHILD HEALTH RESEARCH INSTITUTE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; JANUS KINASE 2; STEROID; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BONE MARROW BIOPSY; BONE MARROW CELL; CLINICAL FEATURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; ERYTHROCYTOSIS; EXON; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MOLECULAR CLONING; MORTALITY; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; STEROID THERAPY; THROMBOCYTOPENIA;

EID: 42349112583     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404971     Document Type: Letter

References (8)

1. Kaushansky K. The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54-year-old speculation comes of age. Best Pract Res Clin Haematol 2007; 20: 5-12.
2. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M et al. The JAK2V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. PNAS 2006; 103: 6224-6229.
3. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
4. Scott LM, Tong W, Levine M, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. NEJM 2007; 356: 459-468.
5. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2 617F-negative polycythemia vera. Leukemia 2007; Epub ahead of print (June 28): 1-4.
6. Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S et al Acquired mutation of the tyrosine kinase JAK2 in human myelo-proliferative disorders. Lancet 2005; 365: 1054-1061.
7. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al Proposals and rationale for revision of the World Health Organisation diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
8. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. BJH 2007; 136: 745-751.